Why the study?
Does fenfluramine-associated pulmonary arterial hypertension differ in survival and clinical features compared to idiopathic and familial pulmonary arterial hypertension?
Does fenfluramine-associated pulmonary arterial hypertension differ in survival and clinical features compared to idiopathic and familial pulmonary arterial hypertension?
No takes yet. Share an insight, caveat, or question.
Fen-PAH survival matches idiopathic PAH; leaves open whether clinical features or therapies differ.
Souza et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: